经审核，监事会认为，公司《2025 年半年度报告》及其摘要的编制和审议 程序规范合法，符合法律、法规、公司章程及监管机构的规定，公司《2025 年 半年度报告》公允地反映了公司报告期内的财务状况和经营成果，所包含的信息 从各个方面真实地反映出公司报告期内的经营管理和财务状况等事项，所披露的 信息真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。未发现参与 公司 2025 年半年度报告编制和审议的人员有违反保密规定及损害公司利益的行 为。 表决结果：3 票同意，0 票反对，0 票弃权；获全体监事一致通过。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《2025 年半年度报告》及其摘要。 证券代码：688137 证券简称：近岸蛋白 公告编号：2025-035 苏州近岸蛋白质科技股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）第二届监事会第九 次会议于 2025 年 ...

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Suzhou Novoprotein Scientific Inc. for the first half of 2025, emphasizing its focus on innovation and market adaptation in the biopharmaceutical sector [4][6]. Financial Performance - The company's revenue for the first half of 2025 was approximately 72.09 million RMB, representing a 20.85% increase compared to 59.66 million RMB in the same period last year [5]. - The total profit for the period was a loss of approximately 28.92 million RMB, compared to a loss of 16.48 million RMB in the previous year [5]. - The net profit attributable to shareholders was approximately -24.22 million RMB, compared to -8.91 million RMB in the same period last year [5]. - The net cash flow from operating activities was -14.08 million RMB, a significant decrease from 23.30 million RMB in the previous year, reflecting a 160.45% decline [5]. Business Overview - The company specializes in the research, development, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, providing comprehensive solutions in biopharmaceuticals, in vitro diagnostics, and life sciences [6][8]. - The company has developed a total of 3,566 types of target and factor proteins, focusing on areas such as oncology, metabolism, and autoimmune diseases [8][9]. - The company has 166 types of recombinant antibodies, which are used in immunodiagnostic reagents, new vaccines, and antibody drugs [9]. Strategic Initiatives - The company is actively engaging in gene and cell therapy, leveraging its GMP production technology to provide tools and solutions for gene editing [6][8]. - The company is enhancing its RNA production processes and expanding its product offerings in RNA applications to meet diverse customer needs [6][8]. - The company aims to address the "bottleneck" issues in basic biopharmaceutical raw materials by integrating its seven comprehensive technology platforms and 23 core technologies [8]. Industry Context - The Chinese government is promoting the integration of biotechnology and information technology, aiming to strengthen the biopharmaceutical industry and support innovation in drug development [7][8]. - Recent government initiatives, including the "High-Quality Development Action Plan for the Pharmaceutical Industry," are expected to boost confidence in the pharmaceutical sector and support the development of innovative drugs [7].

苏州近岸蛋白质科技股份有限公司2025 年半年度报告摘要 公司代码：688137 公司简称：近岸蛋白 苏州近岸蛋白质科技股份有限公司 苏州近岸蛋白质科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在经营过程中可能面临的相关风险因素，敬请查阅本报告第 三节"管理层讨论与分析"之"四、风险因素"。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 不适用 □适用 √不适用 第二节 公司基本情况 公司股票简况 本报告期末 上年度末 增减(%) 总资产 2,198,497,818.86 2,218,110,499.82 -0.88 归属于上市公司股东的 净资产 | | | | | 本报告期比上年同期增 | | | | --- | --- | --- | --- | --- | --- | --- | | | 本报告期 | | 上年同期 | | | | | | | | | 减(%) | | | | 营业收入 | 72,094,559.14 | | 59,655,247.04 ...

民生证券股份有限公司关于 苏州近岸蛋白质科技股份有限公司 使用部分超募资金永久补充流动资金的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的持续督导机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法规 和规范性文件的规定，对近岸蛋白使用部分超募资金永久补充流动资金进行了核 查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2022 年 7 月 25 日出具的《关于同意苏州近岸 蛋白质科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1626 号）批准，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 17,543,860 股，每股发行价格为人民币 106.19 元，募集资金总额为人民币 186,298.25 万元；扣除发行费用后实际的募集资金净额为人民币 174,219.58 万元。 上述募集资金已 ...

苏州近岸蛋白质科技股份有限公司2025 年半年度报告 公司代码：688137 公司简称：近岸蛋白 苏州近岸蛋白质科技股份有限公司 2025 年半年度报告 1 / 209 苏州近岸蛋白质科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的相关风险因素，敬请查阅本报告第 三节"管理层讨论与分析"之"四、风险因素"。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人朱化星、主管会计工作负责人张冬叶及会计机构负责人（会计主管人员）张冬 叶声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者 ...

Group 1 - The company reported a revenue of 72.09 million yuan for the first half of 2025, representing a year-on-year growth of 20.85% [1] - The net loss attributable to shareholders was 24.22 million yuan, compared to a net loss of 8.91 million yuan in the same period last year [1] - The net cash flow from operating activities was -14.08 million yuan, while it was 23.30 million yuan in the same period last year [1]

中国经济网北京8月20日讯近岸蛋白(688137.SH)今日收报45.85元，跌幅2.03%。该股目前处于破发状 态。 近岸蛋白于2022年9月29日在上交所科创板上市，发行价格为106.19元/股，发行股票数量为1,754.3860 万股，保荐人(主承销商)为民生证券股份有限公司(现为"国联民生（601456）证券股份有限公司")，保 荐代表人为王璐、黄立超。 近岸蛋白首次公开发行股票募集资金总额为186,298.25万元，扣除发行费用后募集资金净额为174,219.58 万元。该公司最终募集资金净额较原计划多24,219.58万元。近岸蛋白于2022年9月26日披露的招股说明 书显示，其拟募集资金150,000.00万元，拟分别用于诊断核心原料及创新诊断试剂产业化项目、研发中 心建设项目和补充流动资金。 近岸蛋白首次公开发行股票的发行费用总额为12,078.67万元，其中保荐机构民生证券股份有限公司获得 承销保荐费用9,842.17万元。 ...

Group 1 - The company has approved a share repurchase plan to stabilize its stock price, allowing for the repurchase of its issued A-shares at a price not exceeding 30.68 RMB per share, with a total repurchase fund between 10 million RMB and 20 million RMB [2] - The repurchase period is set for 12 months from the date of the shareholders' meeting that approved the plan [2] - As of July 31, 2025, the company has not yet initiated the stock repurchase and will implement the plan based on market conditions [3] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make decisions based on market conditions, ensuring timely disclosure of progress [4]

Core Viewpoint - Company plans to repurchase shares to stabilize stock price and reduce registered capital, with a total repurchase amount expected between 10 million and 20 million RMB [1][2] Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on September 28, 2024, and will be implemented from October 15, 2024, to October 14, 2025 [1] - The repurchase price will not exceed 30.68 RMB per share, with a total repurchase amount ranging from 10 million to 20 million RMB [1] - As of the announcement date, no shares have been repurchased, and the total repurchased shares account for 0% of the total share capital [1] Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has not yet initiated the stock repurchase and will implement the plan based on market conditions [2] - The company is committed to adhering to relevant regulations during the repurchase period and will disclose progress regularly [2]

Company Overview - Nearshore Protein (SH 688137) announced on August 4 that as of July 31, 2025, the company has not yet initiated a stock buyback, but will consider implementing the buyback plan based on market conditions [1] Financial Performance - For the year 2024, the revenue composition of Nearshore Protein is as follows: - Life Sciences Basic Research: 43.35% - In Vitro Diagnostics: 18.64% - Biopharmaceuticals: 16.2% - Other Businesses: 12.54% - mRNA Vaccine Drugs: 9.27% [1] Market Capitalization - As of the report, the market capitalization of Nearshore Protein is 3.4 billion yuan [1]